ZAVESCA MIGLUSTAT
Total Payments
$15,380
Transactions
33
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $14,940 | 26 | 1 |
| 2017 | $440.43 | 7 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $10,229 | 12 | 66.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,304 | 1 | 28.0% |
| Food and Beverage | $707.29 | 19 | 4.6% |
| Consulting Fee | $140.68 | 1 | 0.9% |
Ad
Manufacturing Companies
- Actelion Pharmaceuticals, Ltd $15,380
Product Information
- Type Drug
- Total Payments $15,380
- Total Doctors 2
- Transactions 33
About ZAVESCA MIGLUSTAT
ZAVESCA MIGLUSTAT is a drug associated with $15,380 in payments to 2 healthcare providers, recorded across 33 transactions in the CMS Open Payments database. The primary manufacturer is Actelion Pharmaceuticals, Ltd.
Payment data is available from 2017 to 2018. In 2018, $14,940 was paid across 26 transactions to 1 doctors.
The most common payment nature for ZAVESCA MIGLUSTAT is "Travel and Lodging" ($10,229, 66.5% of total).